{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-061208","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2026-05-14T20:23:01+00:00","discovered_at":"2026-05-14T20:24:00.210456+00:00","generated_at":"2026-05-14T20:25:49.491048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results","bullets":["Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.","Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.","Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.","Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.","Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-061208","json":"https://secwatch.observer/filing/0001104659-26-061208.json","markdown":"https://secwatch.observer/filing/0001104659-26-061208.md","text":"https://secwatch.observer/filing/0001104659-26-061208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/0001104659-26-061208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:25:49.491048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3d6c8e6941be5fc34f333e0bf0be59d5eb4f31a","claim":"Fortress Biotech, Inc. reported the first quarter ended March 31, 2026 results: net income $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted).","evidence_excerpt":"Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/0001104659-26-061208-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}